Labcorp to offer FDA-cleared Alzheimer's blood test for primary and specialty care
Labcorp will offer the first FDA-cleared single-biomarker blood test that can both rule in and rule out amyloid pathology associated with Alzheimer’s disease in primary and specialty care. The test expands Labcorp’s diagnostic reach into a large unmet-care pathway, but the commercial contribution and rollout economics are not yet disclosed.
PR NEWSWIRE / FILEThe story
The Elecsys pTau-217 test measures phosphorylated Tau 217, a biomarker associated with amyloid pathology and Alzheimer's disease. Labcorp said the test is FDA-cleared for use across specialty and primary care settings, distinguishing it from tests limited to narrower clinical environments.
The product connects Labcorp with Roche's Elecsys diagnostic platform and with clinicians evaluating patients for possible Alzheimer's disease. Its ability to rule in and rule out amyloid pathology could allow blood testing to serve as an earlier screening step before more specialized workups.
Our read · Mon, Aug 24
The FDA-cleared Alzheimer’s blood test adds a differentiated growth option for LH, though the near-term earnings read remains unquantified.
Why. The product gives LH a regulatory-backed offering that can broaden testing beyond specialty-care channels, adding a potential growth vector to a business that reported $14.0B of revenue and 7.2% YoY growth in FY 2025. The trade is constructive but measured because the announcement supplies no pricing, volume, reimbursement, or revenue forecast to support a larger immediate repricing.
Both cases
What could change this view: The setup fails if primary-care adoption, reimbursement, or test volume develops slowly and the product produces little incremental revenue relative to LH’s $14.0B base.
Who reported it · 1
Keep reading
Latest on the Wire
Trump threatens overseas AI data-centre ban for US firmsBitcoin drops below $59,000 as cash rush revives summer-low testGreer says US chip curbs will close China export-control loopholesBlackRock bitcoin ETF posts $541.1 million outflow as tech sell-off spreadsPoland says Russian missiles and drone crashed during Ukraine assaultContinue on the Wire →Latest on the Wire
Anthropic debut fails to halt technology-led slide in US stocksUS MATCH Act puts ASML at center of China chip export disputeBeijing plans to bar young red-chip firms from overseas listingsGerman producer prices jump 8.1% in October as industrial inflation acceleratesContinue on the Wire →Top this week
Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangAnthropic IPO could become the largest in US history on ThursdayAbout this report
Reported by PR Newswire as Labcorp to Offer First FDA-Cleared Blood Test to Detect Alzheimer's Disease Pathology in Both Primary and Specialty Care Settings
, . Who answers for this
The only report in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →